Biotest AG: Biotest Supervisory Board extends Management Board contract of Dr Jörg Schüttrumpf by 5 years
EQS-News: Biotest AG
/ Key word(s): Personnel
PRESS RELEASE
Biotest Supervisory Board extends Management Board contract of Dr Jörg Schüttrumpf by 5 years
As 'Chief Scientific Officer', Dr Schüttrumpf is responsible for research and development within the Biotest Group, including drug safety and regulatory affairs. Dr Schüttrumpf has been Head of Global Research at Biotest AG since 2012 and Head of Research and Development since 2015.
In addition, the Spanish parent company of Biotest AG, Grifols S.A., has asked Dr Schüttrumpf to assume the role of 'Chief Scientific Innovation Officer' for the entire Grifols Group. In this role, he will drive the strategic growth focus as a provider of innovative therapeutics for both companies.
"We are very pleased to have Dr Schüttrumpf as a long-term member of the Board of Management and congratulate him on his additional new role in the Grifols Group. He has been very successful in developing the research and development area at Biotest and is a leader with an impressive track record," emphasises Dr Bernhard Ehmer, Chairman of the Supervisory Board of Biotest AG.
About Biotest: Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,300 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).
Dr Monika Buttkereit Phone: +49-6103-801-4406
PR contact Dirk Neumüller Phone: +49-6103-801-269 Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.com Ordinary shares: securities’ ID No. 522720; ISIN: DE0005227201
Disclaimer
04.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Biotest AG |
Landsteinerstraße 5 | |
63303 Dreieich | |
Germany | |
Phone: | 0 61 03 - 8 01-0 |
Fax: | 0 61 03 - 8 01-150 |
E-mail: | ir@biotest.com |
Internet: | www.biotest.de |
ISIN: | DE0005227235, DE0005227201 |
WKN: | 522723, 522720 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1718261 |
End of News | EQS News Service |
Editor Details
-
Company:
- EQS Newsfeed
- Website: